OneSource's Partner Dr. Reddy's Laboratories receives Health Canada Approval for Generic Semaglutide Injection

OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) has announced that its partner Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY), has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic®. OneSource serves as the CDMO partner on this program, providing scale-up and manufacturing support.

The partnership is designed to ensure reliable and scalable commercial supply from OneSource's US-FDA approved flagship manufacturing facility in Bengaluru.

Mr. Neeraj Sharma, CEO & MD, OneSource Speciality Pharma Limited, speaking on the development, said: "We are pleased to announce that our partner Dr. Reddy's has received approval from Health Canada for Semaglutide Injection, a generic version of Ozempic®. This approval further strengthens our collaboration, combining Dr. Reddy's expertise in peptide development with OneSource's CDMO capabilities."

Shares of Onesource Specialty Pharma Limited was last trading in BSE at Rs. 1762.50 as compared to the previous close of Rs. 1828.20. The total number of shares traded during the day was 6577 in over 1007 trades.

The stock hit an intraday high of Rs. 1835.00 and intraday low of 1750.00. The net turnover during the day was Rs. 11760942.00.

Source : Equity Bulls

Keywords

OnesourceSpecialtyPharma INE013P01021 DrReddysLaboratories RDY HealthCanada Approval GenericSemaglutideInjection